ICON issues 2025 guidance, stock slides 8%
ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...
Icon’s Strategic Positioning and Undervalued Potential: A Buy Recommendation
Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 ...
ICON Issues Financial Guidance for Full Year 2025
Full year 2025 revenue guidance in the range of $8,050 - $8,650 million; midpoint of $8,350 million representing growth of ...
Buy Rating on Icon: Navigating Short-term Challenges with Strong Competitive Position and Strategic Initiatives
Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Icon (ICLR – Research Report). The associated price ...
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...